Clinical Trials

A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good General Health

January 25, 2022

To assess the safety, tolerability, and ability to evaluate a desired immune response of two vaccinations – a prime (eOD-GT8 60mer) mRNA vaccine and boost (Core-g28v2 60mer) mRNA vaccine, in uninfected healthy adults.